How Johnson & Johnson vaccine authorization could improve rollout

Dr. Ashish Jha, Dean of the Brown University School of Public Health, breaks down the new data behind the single-dose vaccine and how it could protect against emerging variants.
2:29 | 02/25/21

Coming up in the next {{countdown}} {{countdownlbl}}

Coming up next:

{{nextVideo.title}}

{{nextVideo.description}}

Skip to this video now

Now Playing:

{{currentVideo.title}}

Comments
Related Extras
Related Videos
Video Transcript
Transcript for How Johnson & Johnson vaccine authorization could improve rollout
We are joined by Dr. Ashish jha. Thanks for joining us. Let's talk about the New York variant. How concern something it to you? Yeah, good morning, George. Thanks for having me on. We don't know much about it yet. I think we're going to see things like this. I'm not super concerned yet. I remain optimistic our vaccines will work against it so I don't think we're at a point where we need to be excessively concerned. There is a lot of optimism over the Johnson & Johnson single dose. We know it works well to prevent hospitalizations and deaths but doesn't score quite as effectively on preventing transmission as we've seen moderna and pfizer. What's your take on it? Yeah, my take is at the end of the day this is a very, very good vaccine. I certainly would take it and have my family members take it. As you said it prevents hospitalizations and deaths. That's what we care about and the bottom line is it's still quite effective at preventing regular infections but again the bottom line is hospitalizations and deaths and that's where it's excellent. What do we know about the effectiveness now of all the vaccines against the variants that are cropping up all over the world? Yeah, I remain pretty optimistic. Against the uk variant these are very good. Against any of the variants that have popped up from the united States they're very good. The one that has had some concern is the south African variant. The vaccines seem to still work pretty well. But we may need to at some point down the road update our vaccines. If people have a choice which vaccine should they take? I really think and I mean this, this is what I said to my family, people should get whatever vaccine is available and not worry about picking between all three of these excellent vaccines. You think whichever one you can get whenever you can get it, you should get it. Absolutely. Absolutely. And how about the overall situation right now? We're still seeing cases and hospitalizations and deaths come down. How much longer do you think we're going to have to have strict social distancing mask wearing? Yeah, it's a very good question. My take is we still -- the uk variant is the one I'm still worried about, again mid to late March. We have to get through that. Once we get into April, I hope that a lot of people have been the uk variant will not be dominating us in the same way and at that point I think we can really start making some decisions about relaxing a lot of the restrictions. Relatively normal summer. Yeah, relatively former summer. I'm really excited about it. Thanks for your time. Reason for excitement indeed, George.

This transcript has been automatically generated and may not be 100% accurate.

{"duration":"2:29","description":"Dr. Ashish Jha, Dean of the Brown University School of Public Health, breaks down the new data behind the single-dose vaccine and how it could protect against emerging variants.","mediaType":"default","section":"ABCNews/GMA","id":"76105956","title":"How Johnson & Johnson vaccine authorization could improve rollout","url":"/GMA/News/video/johnson-johnson-vaccine-authorization-improve-rollout-76105956"}